Marktinformationen

TOKYO (dpa-AFX) - Takeda Pharmaceutical Co. Ltd. (TAK), Friday announced
that the company has received positive feedback from the European Medicines
Agency's Committee for Medicinal Products for Human Use or CHMP regarding usage
of recombinant ADAMTS13 for the treatment of ADAMTS13 deficiency in children and
adult patients with cTTP.

The company stated that cTTP is an ultra-rare, chronic and debilitating clotting
disorder associated with life-threatening acute events and debilitating chronic
symptoms, or thrombotic thrombocytopenic purpura manifestations.

Based on the feedback, the European Commission will provide marketing
authorization for recombinant ADAMTS13 in the European Union.

Earlier, recombinant ADAMTS13 was approved by the U.S. Food and Drug
Administration and the Japanese Ministry of Health, Labour, and Welfare.

Currently, Takeda's stock is moving up 1.57 percent, to $13.23 on the New York
Stock Exchange.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX